GlassScriptPhysician profile
Alexandra E Mullins
NPI 1689224867
$4,005.12
in general payments reported to CMS, 2019-2025
33 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $661 · 2022: $374 · 2023: $774 · 2024: $1,175 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,970.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,605.07 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Preventric Diagnostics, INC. | $407.73 | 2021 | |
| Lilly USA, LLC | $211.01 | 2023-2025 | Zepbound, Mounjaro, Kisunla |
| Daiichi Sankyo INC. | $203.19 | 2021-2025 | Injectafer |
| Amgen INC. | $196.72 | 2024-2025 | Repatha, Evenity, Otezla |
| Abbvie INC. | $157.61 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.74 | 2023-2025 | |
| Glaxosmithkline, LLC. | $137.98 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.84 | 2023-2024 | Jardiance |
| Exact Sciences Corporation | $91.23 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $88.66 | 2023-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Otsuka America Pharmaceutical, INC. | $84.09 | 2023-2025 | Nuedexta, Rexulti |
| Exeltis, USA INC. | $78.55 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $49.48 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $49.15 | 2021-2024 | Farxiga |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $43.90 | 2025 | Neffy |
| Idorsia Pharmaceuticals US INC | $43.30 | 2023-2024 | Quviviq |
| Grifols USA, LLC | $28.14 | 2025 | Prolastin-C Liquid |
| Intrabio INC | $25.54 | 2025 | Aqneursa |
| Agios Pharmaceuticals, INC. | $24.84 | 2024 | Pyrukynd |
| Corcept Therapeutics | $22.77 | 2025 | Korlym |
| Edwards Lifesciences Corporation | $21.17 | 2022 | |
| Dexcom, INC. | $19.18 | 2023 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $18.67 | 2024 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $18.29 | 2022 | |
| Pfizer INC. | $16.70 | 2025 | |
| Azurity Pharmaceuticals, INC. | $16.31 | 2025 | Alvesco |
| Verrica Pharmaceuticals INC. | $16.11 | 2024 | Ycanth |
| Insulet Corporation | $14.92 | 2025 | Omnipod |
| Alexion Pharmaceuticals, INC. | $13.93 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.82 | 2025 | Zoryve |
| Arbor Pharmaceuticals, INC. | $13.31 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Mullins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.